Head & Neck
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Head & Neck Cancer Take Home Messages
FEATURING
Paolo Bossi
- 312 views
- October 8, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Head & Neck Cancer Highlights
FEATURING
Nabil Saba
- 307 views
- September 23, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: 3-Weekly vs. Weekly Cisplatin in High-Risk HNSCC Post-Op CRT - Final Results of JCOG1008
FEATURING
Makoto Tahara
- 181 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Avelumab-Cetuximab-RT vs. SoC in Locally Advanced HNSCC - Final Analysis From the REACH Trial
FEATURING
Makoto Tahara
- 138 views
- September 20, 2024
ecancer
ESMO 2024 Insights: EA3163 Trial - Chemo Followed by Surgery & PORT vs. Surgery & PORT for Organ Preservation of T3 & T4a (Selected T4b) Sinonasal Squamous Cell Carcinoma
FEATURING
Nabil Saba
- 23 views
- October 14, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TACTI-003 - Eftilagimod Alpha + Pembro vs. Pembro Alone in 1L Recurrent/Metastatic HNSCC
FEATURING
Hisham Mehanna
- 17 views
- October 14, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Sequential vs. Induction CT With Concurrent CRT for Locoregionally Advanced Nasopharyngeal Carcinoma
FEATURING
Hisham Mehanna
- 37 views
- October 14, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Neoadjuvant Chemo Followed by Surgery & Post-Operative RT vs. Surgery & Post-Operative RT for Organ Preservation of T3 & T4a Nasal and Paranasal Sinus SCC
FEATURING
Nabil Saba
- 58 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: GORTEC 2017-01 REACH Trial - Avelumab-Cetuximab-RT vs. Standards of Care in Patients With Locally Advanced SCC of Head & Neck
FEATURING
Yungan Tao
- 59 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Setanaxib + Pembro in Recurrent or Metastatic HNSCC
FEATURING
Makoto Tahara
- 89 views
- September 20, 2024